Latest On Xenetic Biosciences, Inc (XBIO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-16 20:33 EST | News | Xenetic Bio cut to Neutral at H.C. Wainwright on lack of catalysts | N/A |  |
| 2023-05-12 16:22 EST | News | Xenetic Biosciences announces reverse stock split of common stock | N/A | |
| 2023-03-23 09:59 EST | News | Xenetic Biosciences reports FY results | N/A | |
| 2023-01-17 13:42 EST | News | Xenetic rises ~10% on upcoming Canadian patent for methods to improve cancer therapy | N/A | |
| 2022-11-11 01:24 EST | News | Xenetic Biosciences GAAP EPS of -$0.06, revenue of $411.95M | N/A | |
| 2022-08-12 10:01 EST | News | Xenetic Biosciences reports Q2 results | N/A | |
| 2022-08-02 22:54 EST | News | Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer | N/A | |
| 2022-07-07 20:36 EST | News | Xenetic inks clinical manufacturing contract with Catalent | N/A | |
| 2022-04-27 13:51 EST | News | Xenetic stock rises 10% on license deal for CLS Therapeutics' cancer drugs platform | N/A | |
| 2022-03-23 17:58 EST | News | Xenetic Biosciences GAAP EPS of -$0.55, revenue of $1.16M | N/A | |
| 2021-11-12 11:17 EST | News | Xenetic Biosciences EPS misses by $0.01, beats on revenue | N/A | |
| 2021-09-09 14:39 EST | News | Xenetic Bio secures new U.S. patent for CAR T platform technology | N/A | |
| 2021-08-13 23:42 EST | News | Xenetic Biosciences EPS beats by $0.03, beats on revenue | N/A | |
| 2021-07-26 07:43 EST | News | Xenetic Biosciences rallies 45% on $12.5M private placement | N/A | |
| 2021-07-24 03:05 EST | News | Xenetic Biosciences more than doubles in value to reach two-year high | N/A | |
| 2021-03-29 20:21 EST | News | Xenetic Biosciences shares rise on approval to start XCART exploratory study | N/A | |
| 2021-03-18 13:55 EST | Earnings Estimate | An EPS average of -$0.13 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-03-18 13:55 EST | Earnings Estimate | An EPS average of -$0.13 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2021-03-17 14:13 EST | Earnings Estimate | An EPS average of -$0.50 is estimated for the 2022 year. | Sell | |
| 2021-01-12 01:03 EST | Analyst Rating | The Analyst Target Price has increased from $2.25 to $3.75. | Buy | |
| 2020-12-10 20:48 EST | News | Xenetic Biosciences launches $6M registered direct offering priced at-the-market | N/A | |
| 2020-12-10 03:08 EST | News | Xenetic soars after PolyXen data from late-stage study in kidney disease-related anemia | N/A | |
| 2020-11-26 22:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-24 09:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-22 19:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-18 13:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 13:45 EST | News | Xenetic Biosciences reports Q3 results | N/A | |
| 2020-11-08 01:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 14:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 06:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-15 10:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 10:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 05:44 EST | News | Xenetic Biosciences EPS beats by $0.07, beats on revenue | N/A | |
| 2020-08-06 09:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 22:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 18:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 10:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-16 16:52 EST | News | Xenetic Bio up 8% on XCART deal | N/A | |
| 2020-06-14 06:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 07:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-02 06:17 EST | Earnings Estimate | An EPS average of -$0.40 is estimated for the quarter ending on September 30, 2020. | Sell | |
| 2020-06-02 06:17 EST | Earnings Estimate | An EPS average of -$0.38 is estimated for the quarter ending on June 30, 2020. | Sell | |
| 2020-06-02 06:17 EST | Analyst Rating | The Analyst Target Price has decreased from $2.5 to $2.25. | Neutral | |
| 2020-05-27 06:46 EST | Financials | Company financials have been released. | Neutral | |
About Xenetic Biosciences, Inc (XBIO):
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and novel oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
General
- Name Xenetic Biosciences, Inc
- Symbol XBIO
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 4
- Last Split Factor1:12
- Last Split Date2019-06-25
- Fiscal Year EndDecember
- IPO Date2014-06-30
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.xeneticbio.com
View More
Valuation
- Trailing PE 0.82
- Price/Sales (Trailing 12 Mt.) 51.9
- Price/Book (Most Recent Quarter) 2.82
- Enterprise Value Revenue 50.38
- Enterprise Value EBITDA 0.01
View More
Financials
- Most Recent Quarter 2020-09-30
- Current Year EPS Estimate -$0.80
- Next Year EPS Estimate -$0.51
- Next Quarter EPS Estimate -$0.19
- Operating Margin -1074%
- Return on Assets -17%
- Return on Equity -74%
- Revenue 436942
- Earnings Per Share -$12.32
- Revenue Per Share $0.07
- Gross Profit 436942
- Quarterly Earnings Growth 786.7%
View More
Highlights
- Market Capitalization 22.57 million
- EBITDA -6153011
- Analyst Target Price $3.75
- Book Value Per Share $1.40
View More
Share Statistics
- Shares Outstanding 8.75 million
- Shares Float 7.79 million
- % Held by Insiders 1058%
- % Held by Institutions 0.86%
- Shares Short 137348
- Shares Short Prior Month 202285
- Short Ratio 0.25
- Short % of Float 2%
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 2.5
- 52 Week High $3.84
- 52 Week Low $0.5
- 50 Day Moving Average 2.75
- 200 Day Moving Average 1.71
View More
Dividends
- Dividend Date 2019-06-25
- ExDividend Date N/A
- Dividend Yield 0%
View More
Xenetic Biosciences, Inc (XBIO) Dividend Calendar:
XBIO's last dividend payment was made to shareholders on June 25, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Xenetic Biosciences, Inc (XBIO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | -$0.16 | -$0.20 | 20% | |
| 2020-09-30 | 2020-11-12 | $N/A | -$1.20 | -$0.16 | -674.19% |
| 2020-06-30 | 2020-08-12 | $112927 | -$0.15 | -$0.22 | 31.82% |
| 2020-03-31 | 2020-05-14 | $56749 | -$0.19 | -$0.37 | 48.65% |
| 2019-12-31 | 2020-03-26 | $17066 | -$0.20 | -$0.38 | 47.37% |
| 2019-09-30 | 2019-11-14 | $N/A | -$2.67 | ||
| 2019-06-30 | 2019-08-14 | $N/A | -$1.56 | ||
| 2019-03-31 | 2019-05-13 | $N/A | -$6.45 | ||
| 2018-12-31 | 2019-03-29 | $N/A | -$2.09 | ||
| 2018-09-30 | 2018-11-09 | $N/A | -$2.31 | ||
| 2018-06-30 | 2018-08-10 | $N/A | -$2.78 | ||
| 2018-03-31 | 2018-05-15 | $N/A | -$2.51 | ||
| 2017-12-31 | 2018-03-30 | $7.5 million | $6.12 | ||
| 2017-09-30 | 2017-11-14 | $85000 | -$3.12 | -$4.92 | 36.59% |
| 2017-06-30 | 2017-08-14 | $N/A | -$4.08 | -$4.68 | 12.82% |
| 2017-03-31 | 2017-05-15 | $N/A | -$4.08 | -$2.52 | -61.9% |
| 2016-12-31 | 2017-03-31 | $3 million | -$3.60 | -$2.28 | -57.89% |
| 2016-09-30 | 2016-11-07 | $N/A | -$3.30 | -$0.19 | -1637.21% |
| 2016-06-30 | 2016-06-30 | $N/A | -$73.45 | ||
| 2016-03-31 | 2016-03-31 | $N/A | -$9.34 | ||
| 2015-12-31 | 2015-12-31 | $N/A | -$9.49 | ||
| 2015-09-30 | 2015-09-30 | $N/A | -$15.10 | ||
| 2015-06-30 | 2015-06-30 | $N/A | -$3.20 | ||
| 2015-03-31 | 2015-03-31 | $N/A | -$6.91 | ||
| 2014-12-31 | 2014-12-31 | $N/A | -$12.23 | ||
| 2014-09-30 | 2014-09-30 | $N/A | -$9.26 | ||
| 2014-06-30 | 2014-06-30 | $N/A | -$8.03 | ||
| 2014-03-31 | 2014-03-31 | $N/A | -$11.83 | ||
| 2013-06-30 | 2013-08-31 | -$2.23 | |||
| 2013-03-31 | 2013-05-31 | -$0.40 | |||
| 2012-12-31 | 2013-02-28 | $0.44 | |||
| 2012-09-30 | 2012-11-30 | -$0.42 | |||
| 2012-06-30 | 2012-08-31 | -$1.50 |
Xenetic Biosciences, Inc (XBIO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | 307900 | 359651 | 417401 | 3.52 million |
| Income Before Tax | N/A | -953642 | -1.18 million | -1.17 million | -8.9 million |
| Selling General Administrative | N/A | 787486 | 927880 | 1.93 million | 2.14 million |
| Gross Profit | N/A | N/A | N/A | 17066 | N/A |
| Ebit | N/A | -975352 | -1.22 million | -2.33 million | -5.66 million |
| Operating Income | N/A | -982459 | -1.23 million | -2.33 million | -5.66 million |
| Income Tax Expense | -2.92 million | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | 112927 | 56749 | 17066 | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | 192 | -134 | 1.16 million | -3.24 million |
| Net Income From Continuing Operations | N/A | -953642 | -1.18 million | -1.17 million | -8.9 million |
| Net Income Applicable to Common Shares | -7.56 million | -953642 | N/A | -1.17 million | -10.31 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | 1145 | -576334 | N/A | -282132 | -626596 |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | 1200 | 13.43 million |
| Change to Operating Activities | 105466 | 254034 | N/A | -355851 | 477546 |
| Change in Cash | N/A | -1.3 million | -1 million | -1.68 million | 11.01 million |
| Total Cash from Operating Activities | -1.01 million | -1.3 million | -1 million | -1.68 million | -2.42 million |
| Depreciation | N/A | 7107 | 7415 | 7492 | 7404 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 6.44 million | -31905 | N/A | 122986 | 6.63 million |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | 3.71 million | 4.43 million | 4.33 million | 4.62 million |
| Total Stockholder Equity | N/A | 15.36 million | 16.2 million | 17.21 million | 18.26 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | N/A | 19.06 million | 20.63 million | 21.55 million | 22.88 million |
| Common Stock | 6322 | 6322 | N/A | 6092 | 5660 |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -175.7 million | -168.14 million | -167.19 million | -166.01 million | -164.84 million |
| Other Liabilities | N/A | 2.92 million | N/A | 2.92 million | 2.92 million |
| Other Assets | 704431 | 704431 | N/A | 1.21 million | 709113 |
| Cash | N/A | 8.07 million | 9.37 million | 10.37 million | 12.04 million |
| Total Current Liabilities | 788473 | 787328 | 1.51 million | 1.42 million | 1.7 million |
| Other Stockholder Equity | 253734 | 253734 | N/A | 253734 | 253734 |
| Property, Plant & Equipment | N/A | N/A | N/A | 757 | 1590 |
| Total Current Assets | 7.99 million | 9.12 million | 10.68 million | 11.09 million | 12.92 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 7.91 million | 6.11 million | N/A | 7.97 million | 9.01 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 251033 | 250075 | 1.05 million | 931128 | 1.16 million |
Xenetic Biosciences, Inc (XBIO) Chart:
Xenetic Biosciences, Inc (XBIO) News:
Below you will find a list of latest news for Xenetic Biosciences, Inc (XBIO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Xenetic Biosciences, Inc (XBIO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest XBIO Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 100 | $0.6649 |
| Jun 13, 2022 7:59 PM EST | 100 | $0.6649 |
| Jun 13, 2022 7:59 PM EST | 300 | $0.6649 |
Xenetic Biosciences, Inc (XBIO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316820002051/0001683168-20-002051-index.htm |
| 2019-09-19 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1534525/000000000019013737/0000000000-19-013737-index.htm |
| 2020-01-21 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1534525/000090266420000308/0000902664-20-000308-index.htm |
| 2019-10-23 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1534525/000094480919000072/0000944809-19-000072-index.htm |
| 2019-08-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1534525/000110465919044521/0001104659-19-044521-index.htm |
| 2020-02-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1534525/000110465920013384/0001104659-20-013384-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1534525/000119312520038180/0001193125-20-038180-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1534525/000138713120001537/0001387131-20-001537-index.htm |
| 2019-09-04 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1534525/000153561019000095/0001535610-19-000095-index.htm |
| 2020-01-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1534525/000153561020000031/0001535610-20-000031-index.htm |
| 2019-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1534525/000168316819002639/0001683168-19-002639-index.htm |
| 2019-08-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316819002648/0001683168-19-002648-index.htm |
| 2019-09-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316819002876/0001683168-19-002876-index.htm |
| 2019-09-13 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1534525/000168316819002928/0001683168-19-002928-index.htm |
| 2019-09-19 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1534525/000168316819002980/0001683168-19-002980-index.htm |
| 2019-09-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003103/0001683168-19-003103-index.htm |
| 2019-09-30 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003105/0001683168-19-003105-index.htm |
| 2019-09-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003106/0001683168-19-003106-index.htm |
| 2019-09-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003107/0001683168-19-003107-index.htm |
| 2019-10-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003199/0001683168-19-003199-index.htm |
| 2019-11-08 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003504/0001683168-19-003504-index.htm |
| 2019-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003653/0001683168-19-003653-index.htm |
| 2019-11-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003668/0001683168-19-003668-index.htm |
| 2019-12-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003909/0001683168-19-003909-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003911/0001683168-19-003911-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003913/0001683168-19-003913-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003915/0001683168-19-003915-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003917/0001683168-19-003917-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003919/0001683168-19-003919-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003921/0001683168-19-003921-index.htm |
| 2019-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1534525/000168316819003923/0001683168-19-003923-index.htm |
| 2020-03-26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1534525/000168316820000967/0001683168-20-000967-index.htm |
| 2020-03-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316820000973/0001683168-20-000973-index.htm |
| 2020-04-01 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1534525/000168316820001062/0001683168-20-001062-index.htm |
| 2020-04-02 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1534525/000168316820001069/0001683168-20-001069-index.htm |
| 2020-04-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316820001278/0001683168-20-001278-index.htm |
| 2020-04-29 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1534525/000168316820001321/0001683168-20-001321-index.htm |
| 2020-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316820001564/0001683168-20-001564-index.htm |
| 2020-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1534525/000168316820001566/0001683168-20-001566-index.htm |
| 2020-05-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316820001661/0001683168-20-001661-index.htm |
| 2020-06-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316820001954/0001683168-20-001954-index.htm |
| 2020-06-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316820002051/0001683168-20-002051-index.htm |
| 2020-08-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1534525/000168316820002645/0001683168-20-002645-index.htm |
| 2020-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316820002655/0001683168-20-002655-index.htm |
| 2020-09-30 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1534525/000168316820003318/0001683168-20-003318-index.htm |
| 2020-10-13 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1534525/000168316820003429/0001683168-20-003429-index.htm |
| 2020-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1534525/000168316820003619/0001683168-20-003619-index.htm |
| 2019-09-23 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1534525/999999999519002156/9999999995-19-002156-index.htm |